Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (9564)
All Articles published online
|
Featured Article
|
Publishing Process of This Article
|
Jan 6, 2020 (publication date) through Dec 21, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Clinical Cases
ISSN
2307-8960
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Cui PF, Cong XF, Gao F, Yin JX, Niu ZR, Zhao SC, Liu ZL. Prognostic factors for overall survival in prostate cancer patients with different site-specific visceral metastases: A study of 1358 patients. World J Clin Cases 2020; 8(1): 54-67 [PMID: 31970170 DOI: 10.12998/wjcc.v8.i1.54] |
|---|---|
| URL: | https://www.wjgnet.com/2307-8960/full/v8/i1/54.htm |
| Number | Citing Articles |
| 1 |
Mohamed E. Ahmed, Ahmed M. Mahmoud, Guiseppe Reitano, Wael Zeina, Kelly Lehner, Carter A. Day, Irbaz Riaz, Daniel S. Childs, Jacob J. Orme, A. Tuba Kendi, Geoffrey B. Johnson, R. Jeffrey Karnes, Eugene D. Kwon, Jack R. Andrews. Survival Patterns Based on First-site–specific Visceral Metastatic Prostate Cancer: Are Outcomes of Visceral Metastases the Same?. European Urology Open Science 2024; 66: 38 doi: 10.1016/j.euros.2024.06.006
|
| 2 |
Zeynep Oruç, M. Ali Kaplan, Mustafa Karaağaç, Neslihan Özyurt, Ali Murat Tatlı, Ali Osman Kaya, Serkan Menekşe, Engin Kut, Sinan Koca, Özlem Nuray Sever, İrem Yasin, Senar Ebinç, Esra Zeynelgil, Abdullah Sakin, Nazım Serdar Turhal, Abdurrahman Isikdogan. Efficacy and Tolerability of Current Treatments for Hormone-Refractory Prostate Cancer Patients with Visceral Metastases. Future Oncology 2021; 17(13): 1611 doi: 10.2217/fon-2020-1032
|
| 3 |
Ang Li, Kai Shen, Yiyi Ji, Weiwei Zhang, Bo Liu, Ruopeng Su, Xiang Zhou, Liang Dong, Yinjie Zhu, Baijun Dong, Jiahua Pan, Qi Wang, Wei Xue.
Prognostic value of [
18
F]FDG PET/CT in metastatic hormone-sensitive prostate cancer at initial diagnosis: a retrospective cohort study
. Annals of Medicine 2024; 56(1) doi: 10.1080/07853890.2024.2411017
|
| 4 |
Ahmed Alasker, Tarek Z. Arabi, Mohammad A. Alghafees, Belal N. Sabbah, Saleha Abdul Rab, Abdulrahman K. Alageel, Ahmed Emad Abouelkhair, Abdulmoiz Kaiser Abdulwali, M. Mohanad Imad Al Hennawi, Waleed Fallatah, Ziyad F. Musalli, Yasser A. Noureldin. Prostate cancer among Saudis: a registry review. Annals of Medicine & Surgery 2024; 86(1): 56 doi: 10.1097/MS9.0000000000001448
|
| 5 |
Saira Khan, Sanah Vohra, Laura Farnan, Shekinah N. C. Elmore, Khadijah Toumbou, Madhav K. C., Elizabeth T. H. Fontham, Edward S. Peters, James L. Mohler, Jeannette T. Bensen. Using health insurance claims data to assess long‐term disease progression in a prostate cancer cohort. The Prostate 2022; 82(15): 1447 doi: 10.1002/pros.24418
|
| 6 |
Sabin Goktas Aydin, Yasin Kutlu, Harun Muglu, Ahmet Aydin, Ozgur Acikgoz, Jamshid Hamdard, Ebru Karci, Ahmet Bilici, Omer Fatih Olmez, Ozcan Yildiz. Predictive significance of inflammatory markers and mGPS in metastatic castration-resistant prostate cancer treated with abiraterone or enzalutamide. Cancer Chemotherapy and Pharmacology 2024; 93(1): 71 doi: 10.1007/s00280-023-04592-x
|
| 7 |
Shotaro Nakanishi, Masato Goya, Mitsuyoshi Tamaki, Takuma Oshiro, Seiichi Saito. Three-month early change in prostate-specific antigen levels as a predictive marker for overall survival during hormonal therapy for metastatic hormone-sensitive prostate cancer. BMC Research Notes 2021; 14(1) doi: 10.1186/s13104-021-05641-5
|
| 8 |
Samer Salah, Ramiz Abu‐Hijlih, Fawzi Abuhijla, Faris Tamimi, Abdallah Al‐Tell, Mohammed Shahait. Pretreatment neutrophil‐to‐lymphocyte ratio as a potential prognostic biomarker for newly diagnosed patients with metastatic castration‐sensitive prostate cancer. Cancer Reports 2021; 4(5) doi: 10.1002/cnr2.1392
|
| 9 |
Charlotte L. Deijen, Gerbert L. Vrijenhoek, Eva E. Schaake, Wouter V. Vogel, Luc M.F. Moonen, Floris J. Pos, Henk G. van der Poel, Gerben R. Borst. PSMA-11-PET/CT versus choline-PET/CT to guide stereotactic ablative radiotherapy for androgen deprivation therapy deferral in patients with oligometastatic prostate cancer. Clinical and Translational Radiation Oncology 2021; 30: 1 doi: 10.1016/j.ctro.2021.06.004
|
| 10 |
Shelby A. Labe, Xi Wang, Eric J. Lehrer, Amar U. Kishan, Daniel E. Spratt, Christine Lin, Alicia K. Morgans, Lee Ponsky, Jorge A. Garcia, Sara Garrett, Ming Wang, Nicholas G. Zaorsky. Identification and Validation of the Prognostic Impact of Metastatic Prostate Cancer Phenotypes. Clinical Genitourinary Cancer 2022; 20(4): 371 doi: 10.1016/j.clgc.2022.02.008
|
| 11 |
Andrew J. Armstrong, Taro Iguchi, Arun A. Azad, Arnauld Villers, Boris Alekseev, Daniel P. Petrylak, Russell Z. Szmulewitz, Antonio Alcaraz, Neal D. Shore, Jeffrey Holzbeierlein, Francisco Gomez-Veiga, Brad Rosbrook, Fabian Zohren, Gabriel P. Haas, Georgia Gourgiotti, Nader El-Chaar, Arnulf Stenzl. The Efficacy of Enzalutamide plus Androgen Deprivation Therapy in Oligometastatic Hormone-sensitive Prostate Cancer: A Post Hoc Analysis of ARCHES. European Urology 2023; 84(2): 229 doi: 10.1016/j.eururo.2023.04.002
|
| 12 |
Ramiz Abu-Hijlih, Samer Salah, Haneen Abaza, Ayat Taqash, Hadeel Abdelkhaleq, Akram Al-Ibraheem, Amal Al-Omari. Comprehensive Analysis of Metastatic Prostate Cancer: Real-World Data From the Middle East. JCO Global Oncology 2024; (10) doi: 10.1200/GO.24.00042
|
| 13 |
Mohammed Alshalalfa, Alexander G. Goglia, Nishwant Swami, Bastien Nguyen, Helen Y Hougen, Anwar Khan, Amar U Kishan, Sanoj Punnen, Paul L Nguyen, Brandon A Mahal, Edward Christopher Dee. Determinants of widespread metastases and of metastatic tropism in patients with prostate cancer: A genomic analysis of primary and metastatic tumors. Urologic Oncology: Seminars and Original Investigations 2023; 41(5): 253.e21 doi: 10.1016/j.urolonc.2023.02.006
|
| 14 |
Ishita Sen, Parul Thakral, Priya Tiwari, Vineet Pant, Subha Shankar Das, Divya Manda, Vinod Raina. Therapeutic efficacy of 225Ac-PSMA-617 targeted alpha therapy in patients of metastatic castrate resistant prostate cancer after taxane-based chemotherapy. Annals of Nuclear Medicine 2021; 35(7): 794 doi: 10.1007/s12149-021-01617-4
|
| 15 |
Yixuan Mo, Joseph Adu-Amankwaah, Wenjie Qin, Tan Gao, Xiaoqing Hou, Mengying Fan, Xuemei Liao, Liwei Jia, Jinming Zhao, Jinxiang Yuan, Rubin Tan. Unlocking the predictive potential of long non-coding RNAs: a machine learning approach for precise cancer patient prognosis. Annals of Medicine 2023; 55(2) doi: 10.1080/07853890.2023.2279748
|
| 16 |
Ia. G. Murazov, D. G. Prokhorov, Yu. S. Tareev, R. V. Smirnov. Efficacy of novel androgen axis inhibitors for the treatment of hormone-sensitive prostate cancer in patients with visceral metastases: a systematic review and meta-analysis. Cancer Urology 2022; 18(2): 171 doi: 10.17650/1726-9776-2022-18-2-171-181
|